Outlook Therapeutics, Inc. (OTLK) SEC Filings — 2025
23 SEC filings for Outlook Therapeutics, Inc. (OTLK) in 2025.
Filings
- OTLK Launches LYTENAVA in Europe, Faces US FDA Hurdles for Wet AMD Drug — 10-K · Dec 19, 2025
- Outlook Therapeutics Files 8-K: Other Events — 8-K · Nov 13, 2025
- Outlook Therapeutics Files 8-K — 8-K · Nov 3, 2025
- Outlook Therapeutics Files 8-K — 8-K · Sep 29, 2025
- Outlook Therapeutics Relocates HQ, Reports Officer/Director Changes — 8-K · Sep 5, 2025
- Outlook Therapeutics Files 8-K — 8-K · Sep 2, 2025
- Outlook Therapeutics Files 8-K on Financials — 8-K · Aug 14, 2025
- Outlook Therapeutics Launches LYTENAVA, Faces Going Concern Doubts — 10-Q · Aug 14, 2025
- Outlook Therapeutics Appoints New Chief Medical Officer — 8-K · Jul 1, 2025
- Outlook Therapeutics Sells ONS-5010 Assets — 8-K · Jun 2, 2025
- Outlook Therapeutics Files 8-K — 8-K · May 23, 2025
- Outlook Therapeutics Files 8-K on Financials — 8-K · May 15, 2025
- Outlook Therapeutics Files 10-Q for Q2 2025 — 10-Q · May 15, 2025
- Outlook Therapeutics Appoints New Chief Medical Officer — 8-K · Apr 11, 2025
- Outlook Therapeutics Sells ONS-5010 for $10M Cash — 8-K · Apr 8, 2025
- Outlook Therapeutics Files 8-K on Key Corporate Events — 8-K · Mar 14, 2025
- Outlook Therapeutics Prices $10M Private Placement — 8-K · Feb 28, 2025
- Outlook Therapeutics Files 8-K on Financials — 8-K · Feb 14, 2025
- Outlook Therapeutics Reports Q2 Loss, Focus on ONS-5010 — 10-Q · Feb 14, 2025
- Outlook Therapeutics Files Definitive Proxy Statement — DEF 14A · Feb 10, 2025
- Outlook Therapeutics Files 8-K: Agreements, Financial Obligations, and Officer Changes — 8-K · Jan 31, 2025
- Outlook Therapeutics Files 10-K/A Amendment — 10-K/A · Jan 23, 2025
- Outlook Therapeutics Files 8-K with Key Corporate Updates — 8-K · Jan 16, 2025